Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Published:2015-03 Issue:3 Volume:127 Page:319-325
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:Journal of Pharmacological Sciences

Author:

Minami Kentaro,Shinsato Yoshinari,Yamamoto Masatatsu,Takahashi Homare,Zhang Shaoxuan,Nishizawa Yukihiko,Tabata Sho,Ikeda Ryuji,Kawahara Kohich,Tsujikawa Kazutake,Chijiiwa Kazuo,Yamada Katsushi,Akiyama Shin-ichi,Pérez-Torras Sandra,Pastor-Anglada Marcal,Furukawa Tatsuhiko,Yasuo Takeda

Funder

Ministry of Education, Culture, Sports, Science and Technology

Mitsui Life Social Welfare Foundation

Takeda Science Foundation

Suzuken Memorial Foundation

Astellas Foundation for Research on Metabolic isorders

Kodama Memorial Fund for Medical Research

Foundation for Promotion of Cancer Research

Osaka Cancer Research Foundation

The Mochida Memorial Foundation for Medical and Pharmaceutical Research

MINECO

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine

Reference33 articles.

1. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry;Carpelan-Holmstrom;Gut,2005

2. Action of 2',2'-difluorodeoxycytidine on DNA synthesis;Huang;Cancer Res,1991

3. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity;Rauchwerger;Cancer Res,2000

4. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma;Spratlin;Clin Cancer Res,2004

5. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd);Nishio;Cancer Sci,2011

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells;Scientific Reports;2024-06-18

2. Olsalazine pretreatment augments chemosensitivity of gemcitabine in hepatocellular carcinoma;Journal of Biochemical and Molecular Toxicology;2024-05-27

3. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer;Cancer Drug Resistance;2024-01-31

4. Review of the potential of African medicinal plants and their derived products against pancreatic cancer;Advances in Botanical Research;2024

5. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor;PLOS ONE;2023-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3